Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-AB-3PRGD2 in solid tumors
NCT06375564Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Alpha Emitters, Beta Emitters
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-AB-3PRGD2 in solid tumor, sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Objective Response Rate. Started Jun 2024; status: recruiting.
02
Drugs
177Lu-AB-3PRGD2
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06375564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375564.